Supporting you in the fight against COVID-19
At Fresenius Kabi, our purpose is caring for life - to put lifesaving medicines in the hands of people who care for patients and to find solutions to the challenges they face. Never has this been more important than today. Even though right now we are all standing a few feet further apart, we are proud to be working shoulder to shoulder with you and we’re committed to doing everything we can to support the heroic and selfless actions on the front lines of patient care.
As a leading supplier of U.S. sterile injectables – medicines being used throughout the pandemic to help treat respiratory conditions and other complications from COVID-19 - we remain focused on delivering the support our customers need every day. That’s why we’ve ramped up production of critical injectable medicines across our expanding U.S. network. It’s why we’ve deployed essential drugs and devices to distribution centers closer to hospitals across the country. And why we’ve remained steadfast in our commitment to keep one another safe — in our facilities, in our homes, and in our communities.
Here are just some of the ways our team has been working around the clock to assure you can provide excellent care for your patients.

Reliability and Continuity of Supply
Over the last three years, we have invested more than $800 million in three U.S. plants and another $100 million in three new distribution centers throughout the U.S. This capacity expansion has helped us adapt rapidly to today’s shifting customer needs, and is designed to give us the flexibility and capacity to be a reliable partner for caregivers for the foreseeable future.

More than 70 percent of our pharmaceutical products for the U.S. are proudly formulated, filled and packaged at our three U.S. production sites.1 This helps us shorten the time needed to respond to changing customer needs, especially during critical emergency situations.
Fresenius Kabi secured continuity-of-supply agreements with Group Purchasing Organizations in 2019, and during the pandemic we’ve added several new products to these agreements.

In 2020, Fresenius Kabi reprioritized pharmaceutical production to focus on critical drugs such as sedatives, pain medications, antibiotics, paralytics, anti-coagulants and anti-emetics. We’ve increased supply output for these products by 25 percent compared to historical levels. We’ve also increased production levels of a needed vaccine component by more than 500 times to support America’s fast-tracked vaccination efforts, which are designed to help bring the pandemic to an end.
Fresenius Kabi offers a broad portfolio of injectable medicines to support COVID-19 patients. We deliver more than 400 million units1 of injectable medicines in the U.S. each year.
We shipped many products direct from our Fresenius Kabi warehouses to our customers for emergency patient need situations during the initial COVID-19 surge in March and April 2020.
We were granted Emergency Use Authorization from the FDA for a sedative medication to be used in Intensive Care Units.
We have supplied needed medicines to the nation’s strategic national stockpile and we are honored to support America’s pandemic response as we manufacture certain products under the Defense Production Act. At Fresenius Kabi, we’re doing more in America to support excellent, affordable care, and we are committed to serving customers as their partner of choice for critical medicines and technologies.

Staying Safe to Serve You Better
At Fresenius Kabi, our dual priorities since the beginning of the pandemic have been to meet the needs of caregivers and patients by continuing to develop, manufacture and deliver our lifesaving products – while keeping our employees safe. Just like health care workers everywhere, our teams have worked long hours at our plants, laboratories and distribution centers to help strengthen the supply chain of essential medicines and medical technologies.
Thank you for all you do to help patients during this critical time. We want you to know that we are doing everything we can to stay safe so we can continue to provide you with essential medicines for those in greatest need.

Advancing Therapies and Care
We are here to support our customers through our leadership and investment efforts in:
- Parenteral nutrition
- We are supporting leadership efforts for implementation of hospital-wide opioid stewardship programs.
- And, patient safety with ready-to-administer (RTA) injectable drug delivery solutions.
- We are also making substantial investments in RFID technology that eliminates manual tagging and data entry to help improve safety and efficiency.
- And we are investing in the development and launch of Biosimilars to help meet the needs of patients across the U.S.

Getting the Right Products Where They’re Needed
We are working closely with the U.S. Department of Health and Human Services (HHS), the U.S. Food and Drug Administration (FDA) Office of Drug Shortages, the U.S. Federal Emergency Management Agency (FEMA) and the U.S. Drug Enforcement Agency (DEA).
We remain in daily contact with pharmaceutical wholesalers, hospital purchasing groups and multiple professional associations like the American Society of Health-System Pharmacists and the American Society of Anesthesiologists to facilitate support for critically ill patients.

Helping You Make Informed Decisions, Quickly
- Fresenius Kabi product availability information is updated weekly on our website.
- Our Customer Service Team can be contacted Monday through Friday between 7:00AM and 6:00PM (CST) at 1.888.386.1300.